Retatrutide — the investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — has generated more excitement in the obesity medicine space than perhaps any drug in recent memory. The TRIUMPH-4 Phase 3 trial reported a mean weight loss of 28.7% over 68 weeks at the 12mg dose, the highest ever recorded in a Phase 3 obesity trial. Commonly referred to as reta in patient communities, this compound has people asking one very practical question long before an FDA approval date has been announced: how much will retatrutide cost?
The honest answer is that no one outside of Eli Lilly knows yet. But by looking at existing GLP-1 pricing patterns, insurance coverage trends, and what Lilly has done with its other obesity medications, it is possible to make an informed, evidence-based projection.
Retatrutide has no approved price because it is not yet FDA approved. As of April 2026, Lilly has not filed a New Drug Application (NDA) for retatrutide, and an FDA approval timeline has not been publicly confirmed. Any figure circulating online as an "official price" should be treated with skepticism.
That said, the GLP-1 receptor agonist market provides a useful pricing baseline. The two most comparable approved medications — tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy) — carry list prices of approximately $1,000–$1,100 per month and $1,350 per month, respectively, without insurance.
Retatrutide is a more complex molecule than either. As a triple agonist (sometimes called a "triple G" in online patient communities), it engages three receptor pathways rather than two, which typically reflects greater manufacturing complexity. It would be reasonable to anticipate a launch price at or above the current tirzepatide range, though Lilly's final pricing strategy will depend heavily on competitive dynamics, outcomes data, and payer negotiations at the time of approval.
What is clear from the clinical data is that the efficacy justifying that price point is substantial. In the Phase 2 trial published in the New England Journal of Medicine, 70% of participants on the 8mg dose lost at least 20% of their body weight by week 48. At 12mg, 48% lost 25% or more. TRIUMPH-4 extended that trajectory further, with the 28.7% mean weight loss figure now setting a new benchmark for the entire field.
Insurance coverage for obesity medications remains deeply inconsistent across payers, and this is one of the most significant access barriers patients face today — even for drugs that are already approved.
When retatrutide reaches approval, the coverage landscape will depend on the label Lilly receives, the clinical data included in that label, and how aggressively Lilly negotiates with payers. Given the robust cardiometabolic data from Phase 2 — including triglyceride reductions of up to 39% and LDL reductions of approximately 16% at 24 weeks — there may be a stronger case for coverage in patients with metabolic comorbidities than existed for earlier GLP-1 agents.
Employers and self-insured plans are also a growing pathway, particularly as outcomes data continues to build. Patients should not assume coverage will be automatic, even with a strong clinical profile.
As of early 2026, no publicly active Eli Lilly expanded access or compassionate use program for retatrutide has been announced. Expanded access programs — sometimes called compassionate use — are typically reserved for patients with serious or life-threatening conditions who have exhausted other options, and they are granted on a case-by-case basis prior to formal approval.
Lilly does operate savings programs for its approved medications. For example, eligible commercially insured patients using Zepbound (tirzepatide) can access significant monthly savings through Lilly's existing coupon programs. It is reasonable to expect that a similar savings or copay assistance structure would accompany a retatrutide launch, particularly given the competitive pressure from semaglutide and the political scrutiny around drug pricing. However, no such program has been announced, and none should be assumed until Lilly confirms it.
The table below summarizes what is currently known about pricing and efficacy for the major injectable obesity medications, alongside retatrutide's projected position based on Phase 2 and Phase 3 data.
| Medication | Mechanism | Approx. List Price/Month | Mean Weight Loss (Trial) | Trial Duration |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 agonist | ~$1,350 | ~14.9% (STEP-1, 2.4mg) | 68 weeks |
| Zepbound / Mounjaro (tirzepatide) | GLP-1 / GIP dual agonist | ~$1,000–$1,100 | ~20.9% (SURMOUNT-1, 15mg) | 72 weeks |
| Retatrutide (LY3437943) | GLP-1 / GIP / glucagon triple agonist | Not yet approved — no price set | ~28.7% (TRIUMPH-4, 12mg) | 68 weeks |
The efficacy gap between retatrutide and its predecessors is meaningful. Reducing nearly 29% of body weight on average — in a Phase 3 trial — represents a step-change rather than an incremental improvement. Whether that translates to a proportionally higher list price, or whether Lilly prices competitively to capture market share, remains to be seen.
Retatrutide availability in 2026 is possible but not confirmed. The TRIUMPH-4 data release in December 2025 was a significant milestone, but a peer-reviewed Phase 3 publication was still pending as of April 2026, and Lilly had not yet filed an NDA. The FDA's standard review timeline after NDA submission is typically 12 months for a standard review or 6 months for priority review. Without a confirmed submission date, a 2026 approval would require both an expedited submission and a priority designation — neither of which has been publicly announced.
Patients following retatrutide should monitor Lilly's official communications and FDA action dates rather than relying on informal timelines circulating in patient communities.
When retatrutide does reach the market, the questions of cost, insurance coverage, and patient access programs will become urgent and concrete. Planning ahead — understanding payer policies, documenting comorbidities, and having conversations with a treating clinician about medical necessity — can meaningfully improve the likelihood of coverage.
For those who want to stay informed as approval approaches, glp3md.com maintains an updated waitlist and ongoing coverage of new weight loss drug developments in 2026 and beyond. Joining the waitlist ensures access to the latest clinical updates, approval news, and access information as they become available. Joining the waitlist is for informational purposes only — no promises are made regarding medication access, treatment, or prescriptions, as retatrutide is not FDA approved. However, being informed and positioned early is the most practical step available right now.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.